NCT03131999View on ClinicalTrials.gov

LAM Pilot Study With Imatinib Mesylate

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 23, 2018

Primary Completion Date

March 7, 2019

Study Completion Date

March 7, 2019

Conditions
Lymphangioleiomyomatosis
Interventions
DRUG

Imatinib Mesylate 400Mg Capsule

Sirolimus or everolimus will be withdrawn after 28 days if used at baseline

DRUG

Placebo - Capsule

Sirolimus or everolimus will be withdrawn after 28 days if used at baseline

Trial Locations (2)

10032

Columbia University, New York

29425

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

Columbia University

OTHER

lead

Medical University of South Carolina

OTHER

NCT03131999 - LAM Pilot Study With Imatinib Mesylate | Biotech Hunter | Biotech Hunter